Gemtuzumab ozogamicin for untreated acute myeloid leukaemia

2.1 Gemtuzumab ozogamicin (Mylotarg, Pfizer) is indicated 'for the treatment of previously untreated, de novo CD33-positive acute myeloid leukaemia, except acute promyelocytic leukaemia for patients age 15 years and above, in combination with daunorubicin and cytarabine.'

2.2 The gemtuzumab ozogamicin dose is 3 mg/m²/dose (up to a maximum of 1×5-mg vial) infused over a 2-hour period. Induction: gemtuzumab ozogamicin 3 mg/m²/dose (up to a maximum of 5 mg/dose) given on days 1, 4 and 7. Consolidation courses 1 and 2: gemtuzumab ozogamicin 3 mg/m²/dose (up to a maximum of 5 mg/dose) given on day 1 of each course.

2.3 £6,300 per 5-mg vial (excluding VAT; British national formulary [BNF] online [accessed August 2018]). The company has a commercial arrangement. This makes gemtuzumab ozogamicin available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.